BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 16044150)

  • 1. Defining the oncogenic function of the TEL/AML1 (ETV6/RUNX1) fusion protein in a mouse model.
    Fischer M; Schwieger M; Horn S; Niebuhr B; Ford A; Roscher S; Bergholz U; Greaves M; Löhler J; Stocking C
    Oncogene; 2005 Nov; 24(51):7579-91. PubMed ID: 16044150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling first-hit functions of the t(12;21) TEL-AML1 translocation in mice.
    Tsuzuki S; Seto M; Greaves M; Enver T
    Proc Natl Acad Sci U S A; 2004 Jun; 101(22):8443-8. PubMed ID: 15155899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice.
    Bernardin F; Yang Y; Cleaves R; Zahurak M; Cheng L; Civin CI; Friedman AD
    Cancer Res; 2002 Jul; 62(14):3904-8. PubMed ID: 12124316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interphase FISH on TEL/AML1 positive acute lymphoblastic leukemia relapses--analysis of clinical relevance of additional TEL and AML1 copy number changes.
    Peter A; Heiden T; Taube T; Körner G; Seeger K
    Eur J Haematol; 2009 Nov; 83(5):420-32. PubMed ID: 19594616
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
    Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cloning and sequencing of ETV6/RUNX1 (TEL/AML1) variant in acute lymphoblastic leukemia.
    Tiensiwakul P
    Cancer Genet Cytogenet; 2004 Feb; 149(1):85-8. PubMed ID: 15104290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The RAC specific guanine nucleotide exchange factor Asef functions downstream from TEL-AML1 to promote leukaemic transformation.
    Lyons R; Williams O; Morrow M; Sebire N; Hubank M; Anderson J
    Leuk Res; 2010 Jan; 34(1):109-15. PubMed ID: 19628279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection.
    Panzer-Grümayer ER; Cazzaniga G; van der Velden VH; del Giudice L; Peham M; Mann G; Eckert C; Schrauder A; Germano G; Harbott J; Basso G; Biondi A; van Dongen JJ; Gadner H; Haas OA
    Clin Cancer Res; 2005 Nov; 11(21):7720-7. PubMed ID: 16278392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic abnormalities involved in t(12;21) TEL-AML1 acute lymphoblastic leukemia: analysis by means of array-based comparative genomic hybridization.
    Tsuzuki S; Karnan S; Horibe K; Matsumoto K; Kato K; Inukai T; Goi K; Sugita K; Nakazawa S; Kasugai Y; Ueda R; Seto M
    Cancer Sci; 2007 May; 98(5):698-706. PubMed ID: 17374122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preleukemic TEL-AML1-positive clones at cell level of 10(-3) to 10(-4) do not persist into adulthood.
    Olsen M; Madsen HO; Hjalgrim H; Gregers J; Rostgaard K; Schmiegelow K
    J Pediatr Hematol Oncol; 2006 Nov; 28(11):734-40. PubMed ID: 17114960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood leukemia genetic bottleneck phenomenon related to TEL-AML1: the postulation by a mathematical model.
    Ivanovski P; Ivanovski I; Nikolić D; Jovanović I
    Chin Med J (Engl); 2012 Mar; 125(6):1182-5. PubMed ID: 22613552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia.
    Castor A; Nilsson L; Astrand-Grundström I; Buitenhuis M; Ramirez C; Anderson K; Strömbeck B; Garwicz S; Békássy AN; Schmiegelow K; Lausen B; Hokland P; Lehmann S; Juliusson G; Johansson B; Jacobsen SE
    Nat Med; 2005 Jun; 11(6):630-7. PubMed ID: 15908956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ETV6 (TEL)-AML1 pre-B acute lymphoblastic leukaemia cells are associated with a distinct antigen-presenting phenotype.
    Alessandri AJ; Reid GS; Bader SA; Massing BG; Sorensen PH; Schultz KR
    Br J Haematol; 2002 Feb; 116(2):266-72. PubMed ID: 11841426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEL (ETV6)-AML1 (RUNX1) initiates self-renewing fetal pro-B cells in association with a transcriptional program shared with embryonic stem cells in mice.
    Tsuzuki S; Seto M
    Stem Cells; 2013 Feb; 31(2):236-47. PubMed ID: 23135987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of TEL/AML1 fusion gene in Brazilian pediatric patients with acute lymphoblastic leukemia.
    Zen PR; Lima MC; Coser VM; Silla L; Daudt L; Fernandes MS; Neumann J; Mattevi MS; Ortigara R; Paskulin GA
    Cancer Genet Cytogenet; 2004 May; 151(1):68-72. PubMed ID: 15120912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythroid inhibition by the leukemic fusion AML1-ETO is associated with impaired acetylation of the major erythroid transcription factor GATA-1.
    Choi Y; Elagib KE; Delehanty LL; Goldfarb AN
    Cancer Res; 2006 Mar; 66(6):2990-6. PubMed ID: 16540647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TEL/AML1 and immunoreceptor gene rearrangements-which comes first?
    Zuna J; Krejci O; Madzo J; Fronkova E; Sramkova L; Hrusak O; Kalina T; Vaskova M; Stary J; Trka J;
    Leuk Res; 2005 Jun; 29(6):633-9. PubMed ID: 15863202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia.
    Sabaawy HE; Azuma M; Embree LJ; Tsai HJ; Starost MF; Hickstein DD
    Proc Natl Acad Sci U S A; 2006 Oct; 103(41):15166-71. PubMed ID: 17015828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.
    Stams WA; Beverloo HB; den Boer ML; de Menezes RX; Stigter RL; van Drunen E; Ramakers-van-Woerden NL; Loonen AH; van Wering ER; Janka-Schaub GE; Pieters R
    Leukemia; 2006 Mar; 20(3):410-6. PubMed ID: 16424874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter.
    Uchida H; Downing JR; Miyazaki Y; Frank R; Zhang J; Nimer SD
    Oncogene; 1999 Jan; 18(4):1015-22. PubMed ID: 10023677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.